Mebendazole (DB00643): A Comprehensive Pharmacological and Clinical Monograph

Section 1: Drug Identification and Physicochemical Profile

This section establishes the fundamental chemical and physical identity of mebendazole, providing the nomenclature, identifiers, and properties that underpin its formulation, pharmacokinetic behavior, and mechanism of action.

1.1 Nomenclature and Identifiers

Mebendazole is a synthetic small molecule compound recognized across numerous chemical and pharmacological databases by a standardized set of identifiers.[1] Its formal chemical name according to the International Union of Pure and Applied Chemistry (IUPAC) is Methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate, though it is also cited as methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate.[1] The compound is uniquely identified by its Chemical Abstracts Service (CAS) Registry Number, 31431-39-7.[1]

In pharmaceutical and biomedical research, it is cataloged under DrugBank Accession Number DB00643.[1] Other key identifiers include PubChem Compound ID 4030, UNII 81G6I5V05I, and ChEMBL ID CHEMBL685.[1] During its development and in research contexts, it has been referred to by codes such as R 17635 and NSC 184849, and by synonyms including 5-Benzoyl-2-benzimidazolecarbamic acid methyl ester.[3]

Commercially, mebendazole is marketed globally under a wide array of brand names. The most prominent include Vermox, Ovex, and Emverm.[1] Other international brand names include Pantelmin, Lomper (Spain), Surfont (Germany), Bendax (Egypt), Mebex (India), and Antiox (Philippines), reflecting its worldwide use.[5]

1.2 Chemical Structure and Formula

Mebendazole is a synthetic derivative of the benzimidazole class of compounds, which is characterized by a fused benzene and imidazole ring system.[2] Its molecular formula is

C16​H13​N3​O3​.[1] Structurally, it is a carbamate ester and an aromatic ketone.[2] The core structure is a methyl 1H-benzimidazol-2-ylcarbamate, which is substituted at the 5-position of the benzimidazole ring with a benzoyl group.[2] This specific chemical architecture is fundamental to its biological activity and places it within the same therapeutic family as other broad-spectrum anthelmintics like albendazole and fenbendazole.

1.3 Physicochemical Properties

The therapeutic utility and pharmacokinetic profile of mebendazole are directly governed by its distinct physicochemical properties. With a molar mass of approximately 295.298 g·mol⁻¹, it exists physically as a white to slightly yellow or off-white amorphous powder or crystal.[1] It is noted to have a not unpleasant or even pleasant taste, which is advantageous for its oral chewable formulations.[2]

A defining and clinically critical characteristic of mebendazole is its extremely low aqueous solubility. It is classified as practically insoluble in water, as well as in common organic solvents like alcohol and methylene chloride.[2] Quantitative measurements confirm this, with reported solubility values around 0.035 mg/mL (or 35.4 mg/L) at 25 °C.[11] This poor solubility is the primary determinant of its pharmacokinetic behavior. It leads to low and incomplete absorption from the gastrointestinal tract, resulting in a bioavailability of only 2-20%.[1] This characteristic creates a therapeutic paradox: it is highly advantageous for treating intestinal parasites, as it concentrates the drug locally in the gut lumen while minimizing systemic exposure and side effects.[1] However, this same property presents a significant challenge when systemic drug levels are required, such as in the treatment of systemic parasitic diseases or for its repurposed use in oncology.[13] This limitation necessitates clinical strategies to enhance absorption, such as co-administration with high-fat meals or the development of advanced drug delivery systems.[13]

Mebendazole exhibits polymorphism, existing in at least three different crystalline forms: A, B, and C.[18] These polymorphs possess different physical properties, including solubility. In an acidic medium (0.1 M HCl), the solubility follows the order B > C > A, a factor that is highly relevant for pharmaceutical formulation and dissolution kinetics.[18] Other key properties include a high melting point of approximately 288.5 °C and pKa values of 3.43 and 9.93 (uncertain).[2] Based on these properties, mebendazole is categorized under the Biopharmaceutical Classification System (BCS) as Class II or IV, signifying low solubility and variable permeability, which aligns with its observed pharmacokinetic challenges.[11]

Table 1: Key Identifiers and Physicochemical Properties of Mebendazole

Property	Value	Source(s)
IUPAC Name	Methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate	1
CAS Number	31431-39-7	1
DrugBank ID	DB00643	1
PubChem CID	4030	1
UNII	81G6I5V05I	1
Molecular Formula	C16​H13​N3​O3​	1
Molar Mass	295.298 g·mol⁻¹	1
Physical Appearance	White to slightly yellow crystalline powder	2
Melting Point	288.5 °C	2
Aqueous Solubility	Practically insoluble (~0.035 mg/mL at 25 °C)	11
BCS Class	Class II / IV	11
Polymorphic Forms	A, B, C	18

Section 2: Pharmacology and Mechanism of Action

The pharmacological activity of mebendazole is defined by its ability to disrupt fundamental cellular processes through a specific molecular interaction. This core mechanism is the unifying principle that explains its efficacy in two disparate therapeutic fields: parasitology and oncology. By functioning as a potent tubulin modulator, mebendazole effectively targets the cytoskeletal integrity of both parasitic helminths and rapidly dividing mammalian cancer cells.

2.1 Primary Anthelmintic Mechanism

Mebendazole's principal anthelmintic effect is achieved through the targeted disruption of microtubule structures within the intestinal cells of parasitic worms.[1] The drug exhibits a high affinity for and selectively binds to the colchicine-binding site on the β-tubulin subunit of the parasite's tubulin protein.[1] This binding event physically obstructs the polymerization of tubulin dimers into the long, filamentous polymers that form cytoplasmic microtubules.[1]

The resulting loss of the microtubular cytoskeleton triggers a cascade of catastrophic failures in the parasite's cellular functions. Most critically, it incapacitates the absorptive intestinal cells, blocking the uptake of glucose and other essential nutrients from the host's gut.[1] This leads to a rapid depletion of the worm's glycogen stores and a severe reduction in the production of adenosine triphosphate (ATP), the primary energy currency of the cell.[15] The ensuing energy crisis results in the gradual immobilization and paralysis of the helminth, ultimately leading to its death.[1] The dead or debilitated parasites are then expelled from the host's gastrointestinal tract via normal peristalsis over a period of several days.[1] In addition to its effects on adult worms, mebendazole also demonstrates ovicidal activity against the eggs of certain species, such as

Ascaris lumbricoides and Trichuris trichiura, contributing to its overall therapeutic efficacy.[13]

2.2 Selective Toxicity

The clinical success and favorable safety profile of mebendazole as an anthelmintic agent are fundamentally rooted in its selective toxicity. The drug's binding affinity for helminthic β-tubulin is significantly higher than its affinity for the analogous protein in mammals.[15] This differential binding means that at standard therapeutic concentrations, mebendazole is profoundly disruptive to the parasite's cellular machinery while exerting only minimal effects on the host's cells. This selectivity is the key to achieving a wide therapeutic window, allowing for effective parasite eradication with a low incidence of host toxicity.[15]

2.3 Effects on Mammalian Cells and Apoptotic Pathways

Despite its selectivity for parasitic tubulin, mebendazole does interact with and inhibit the polymerization of mammalian tubulin, particularly at the higher concentrations employed in oncological research.[1] This interaction forms the basis of its anti-cancer activity. The primary target in mammalian cells is the mitotic spindle, a highly dynamic microtubule-based structure that is essential for the segregation of chromosomes during cell division (mitosis).[1]

By disrupting the formation and function of the mitotic spindle, mebendazole causes dividing cells to arrest in the M-phase of the cell cycle. This prolonged mitotic arrest is an unsustainable state for the cell and triggers the intrinsic pathway of programmed cell death, or apoptosis.[1] Mechanistically, this has been shown to be mediated through the dephosphorylation of Bcl-2, an anti-apoptotic protein. The inactivation of Bcl-2 allows the pro-apoptotic protein Bax to form dimers, which then initiate the downstream caspase cascade that executes cell death.[1] This specific pathway has been demonstrated to be effective even in chemoresistant melanoma cells.[4]

The mechanism of inducing mitotic arrest via tubulin disruption is a well-established and validated strategy in cancer chemotherapy. It is the same fundamental mechanism employed by classic chemotherapeutic drug classes such as the taxanes (e.g., paclitaxel) and the vinca alkaloids (e.g., vincristine).[21] Therefore, mebendazole is not merely an anthelmintic with incidental anti-cancer properties; it is a legitimate microtubule-destabilizing agent and mitotic inhibitor, providing a strong scientific rationale for its repurposing in oncology.

Section 3: Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The clinical behavior of mebendazole is dictated by its distinct pharmacokinetic profile. Characterized by poor absorption but excellent tissue penetration of the absorbed fraction, its journey through the body explains both its efficacy in localized intestinal infections and its potential for systemic activity at higher doses.

3.1 Absorption and Bioavailability

Following oral administration, mebendazole is poorly and erratically absorbed from the gastrointestinal tract.[1] Its systemic bioavailability is very low, with estimates ranging from 2-10% to 5-20% of the administered dose.[1] This poor absorption is a direct consequence of its low aqueous solubility, which limits its dissolution in the gut lumen, combined with extensive presystemic (first-pass) metabolism in the gut wall and liver.[13]

As a result, systemic plasma concentrations achieved with standard anthelmintic doses are minimal. For instance, following a regimen of 100 mg twice daily for three days, peak plasma levels of mebendazole and its primary metabolite typically do not exceed 0.03 µg/mL and 0.09 µg/mL, respectively.[23] A significant food effect has been observed; co-administration with a high-fat meal can substantially increase the drug's absorption and bioavailability.[13] This is a critical clinical consideration for any indication where achieving systemic therapeutic concentrations is the goal.

3.2 Distribution

Mebendazole exhibits an apparent pharmacokinetic contradiction: despite being poorly absorbed, the small fraction that does enter the systemic circulation distributes exceptionally well into tissues. Once in the bloodstream, it is highly bound to plasma proteins, with a binding fraction of 90-95%.[1]

The drug has a large apparent volume of distribution, estimated at 1 to 2 L/kg, which indicates that it does not remain confined to the bloodstream but penetrates extensively into extravascular tissues.[11] This suggests that while the total quantity of drug entering the body is small, its physicochemical properties—notably its lipophilicity and low molecular weight—make it highly efficient at partitioning from the plasma into peripheral tissues.

Crucially, these properties also allow mebendazole to cross the blood-brain barrier.[13] This capacity for central nervous system penetration is clinically validated by its effectiveness in treating cerebral echinococcosis and is the cornerstone of the rationale for investigating its use in neuro-oncology.[13] This demonstrates that "low bioavailability" does not preclude systemic or CNS activity; even low plasma concentrations can translate into therapeutically meaningful drug levels at the target site, particularly when the high doses used in oncology are administered.

3.3 Metabolism

The absorbed fraction of mebendazole is rapidly and extensively metabolized, primarily by cytochrome P450 enzymes in the liver.[14] The principal metabolic pathway is hydrolysis of the carbamate ester, followed by reduction of the ketone group. The major metabolite is the 2-amino form, 2-amino-5-benzoylbenzimidazole, which, along with other hydroxy and hydroxyamino metabolites, is pharmacologically inactive and devoid of anthelmintic activity.[14] Because metabolism is the primary clearance mechanism, patients with impaired hepatic function or biliary obstruction may experience significantly higher plasma levels of the parent drug, necessitating caution and potential dose adjustments.[11]

3.4 Excretion

The elimination of mebendazole is consistent with its poor absorption. The vast majority (over 90%) of an administered oral dose is excreted unchanged in the feces, having never been absorbed systemically.[1] The small, absorbed fraction is primarily cleared via the bile and subsequently excreted in the feces, with a minor portion (approximately 2-10%) eliminated in the urine, mostly as metabolites.[1] Some evidence suggests the drug may undergo a degree of enterohepatic recirculation.[13]

The plasma elimination half-life of mebendazole is relatively short, averaging 3 to 6 hours in individuals with normal hepatic function.[1] This half-life can be substantially prolonged in patients with cholestatic liver disease or other forms of severe hepatic impairment.[20]

Section 4: Clinical Applications in Helminthiasis

Mebendazole is a cornerstone therapy for the treatment of intestinal worm infections, valued for its broad spectrum of activity against common nematodes and its generally favorable safety profile at standard doses. Its clinical use is well-established, with specific dosing regimens tailored to the type of parasitic infection.

4.1 Approved Indications and Efficacy Spectrum

Mebendazole is a broad-spectrum anthelmintic agent indicated for the treatment of single or mixed gastrointestinal infestations caused by a range of nematode species.[1] In the United States, the Food and Drug Administration (FDA) has approved its use in patients aged two years and older for the following infections [22]:

• Enterobius vermicularis (Pinworm)
• Trichuris trichiura (Whipworm)
• Ascaris lumbricoides (Common Roundworm)
• Ancylostoma duodenale (Common Hookworm)
• Necator americanus (American Hookworm)

It is also used globally for other parasitic diseases, such as guinea worm infections and hydatid disease, although its poor systemic absorption makes other agents preferable for infections that extend beyond the gastrointestinal tract.[1] Off-label use for infections caused by tapeworms has also been reported.[27]

The efficacy of mebendazole varies depending on the target parasite. Clinical studies have demonstrated high parasitological cure rates for pinworm (95%), common roundworm (98%), and hookworm (96%). Its efficacy against whipworm is more moderate, with a reported cure rate of 68%.[23]

4.2 Dosage and Administration

The dosing of mebendazole is highly dependent on the specific helminth being treated and the pharmaceutical formulation available (typically 100 mg or 500 mg chewable tablets).[30] The variability in these regimens is not arbitrary but reflects the drug's differential efficacy against various parasites. For easily treated luminal infections like pinworm, a simple, convenient single dose is sufficient. However, for more tenacious parasites like whipworm, a more intensive, multi-day regimen is required to achieve adequate cure rates, highlighting a clinical trade-off between adherence and maximal efficacy.

The introduction of a single 500 mg dose formulation aims to simplify treatment, particularly in the context of large-scale mass drug administration programs where adherence is a key determinant of success.[24] Standard dosing guidelines are summarized in Table 2.

Table 2: Dosing Regimens for Mebendazole in Approved Helminthic Infections

Indication (Parasite)	Patient Population	100 mg Tablet Regimen	500 mg Tablet Regimen	Clinical Notes
Pinworm (E. vermicularis)	Adults & Children ≥2 years	100 mg as a single dose.	500 mg as a single dose.	A second dose after 2-4 weeks is strongly recommended to prevent reinfection from hatched eggs. All household members should be treated simultaneously. 30
Roundworm (A. lumbricoides)	Adults & Children ≥2 years	100 mg twice daily for 3 consecutive days.	500 mg as a single dose.	If the patient is not cured 3 weeks after treatment, a second course may be necessary. 8
Whipworm (T. trichiura)	Adults & Children ≥2 years	100 mg twice daily for 3 consecutive days.	500 mg as a single dose.	Efficacy is moderate; a second course of treatment may be required if infection persists. 8
Hookworm (A. duodenale, N. americanus)	Adults & Children ≥2 years	100 mg twice daily for 3 consecutive days.	500 mg as a single dose.	If the patient is not cured 3 weeks after treatment, a second course may be necessary. 8

For pediatric patients, mebendazole is generally approved for use in children aged two years and older. However, it can be prescribed by a physician for children between 6 months and two years of age if the clinical benefit is deemed to outweigh the risks.[28] Dosing for children is typically the same as for adults.

Mebendazole is also used off-label at higher doses and for longer durations for more severe or systemic infections, such as capillariasis (200 mg twice daily for 20 days) and trichinellosis (200–400 mg three times daily for 3 days, followed by 400–500 mg three times daily for 10 days).[30]

The tablets are designed to be chewed but can also be swallowed whole or crushed and mixed with food to facilitate administration, especially in young children.[8] It can be taken with or without food, though absorption is enhanced with fatty meals.[32]

4.3 Patient Counseling and Management

Successful treatment of helminthiasis requires more than just medication. Patient education on strict personal hygiene measures is critical to prevent reinfection and the transmission of parasites to others, a point of particular importance for the highly contagious pinworm.[23] Key recommendations include:

• Frequent and thorough handwashing with soap, especially before eating and after using the toilet.
• Keeping fingernails cut short to prevent the accumulation of eggs from scratching.
• Daily changing and washing of underwear, nightclothes, and bed linens.
• Regular cleaning of toilet seats and bedroom floors.[23]

To effectively eradicate the infection within a household or community, it is standard practice to recommend simultaneous treatment for all family members or close contacts, regardless of whether they are symptomatic.[33]

Section 5: Safety and Tolerability Profile

Mebendazole is generally regarded as a safe and well-tolerated medication, particularly at the standard low doses used for treating common intestinal helminth infections. However, its safety profile shifts significantly with the administration of higher doses or for prolonged durations, revealing a dose-dependent pattern of toxicity that is critical to understand for its expanded use in systemic infections and oncology.

5.1 Common and Rare Adverse Effects

At recommended anthelmintic doses, adverse effects are typically mild, transient, and infrequent.[1]

• Common Adverse Effects (Incidence >1%): The most frequently reported side effects are gastrointestinal in nature. These include abdominal pain, diarrhea, flatulence, nausea, and vomiting.[1] These symptoms may be more pronounced in individuals with a very high parasitic burden, possibly due to the expulsion of worms.[39] Other common effects include headache and dizziness.[1]
• Rare Adverse Effects (Incidence <0.1%): A range of less common adverse events have been reported.
• Dermatologic: Rash, pruritus (itching), urticaria (hives), and angioedema (swelling) can occur.[39] Alopecia (hair loss) has been reported, typically associated with higher doses or prolonged use.[1]
• Hepatic: Transient and reversible elevations in liver enzymes (transaminases) have been observed.[1] Postmarketing reports include cases of hepatitis.[11]
• Neurologic: Convulsions or seizures are a rare but serious risk, reported almost exclusively in infants below the age of one year. This has led to a contraindication for its use in this age group for mass treatment programs.[22]
• Renal: Rare cases of glomerulonephritis have been identified in postmarketing surveillance.[11]
• Hypersensitivity: Severe allergic reactions, including anaphylaxis, are possible but rare.[40]

5.2 High-Dose and Long-Term Safety

The safety concerns associated with mebendazole escalate when it is administered at higher doses (e.g., for hydatid disease) or for extended periods, as is necessary for its investigational use in oncology. A clear dose-dependent shift in the primary dose-limiting toxicity is observed. While historical data from high-dose anthelmintic therapy pointed to bone marrow suppression as the most severe risk, recent clinical trials in oncology have identified hepatotoxicity as the more immediate concern at supra-pharmacological doses.

• Hematologic Effects: Myelosuppression is a significant risk with high-dose therapy. Reports include cases of neutropenia (low neutrophil count), severe agranulocytosis (a life-threatening absence of neutrophils), thrombocytopenia (low platelet count), and pancytopenia (a deficiency of all blood cell types).[1] Consequently, regular monitoring of blood counts is mandatory for any patient on a high-dose or prolonged mebendazole regimen.[30]
• Hepatotoxicity: The Phase 1 clinical trial of high-dose mebendazole (up to 200 mg/kg/day) in glioma patients revealed that the primary dose-limiting toxicity was reversible, grade 3 elevation of liver enzymes (ALT and AST), not myelosuppression.[26] This suggests that at these extreme doses, the liver's metabolic capacity becomes saturated, leading to hepatocellular injury before significant bone marrow toxicity manifests. This finding redefines the safety monitoring strategy for its oncological application, placing paramount importance on vigilant and frequent monitoring of liver function tests.[11]

5.3 Use in Specific Populations

• Pregnancy: Mebendazole is classified as FDA Pregnancy Category C.[22] Animal studies, particularly in rats, have demonstrated embryotoxic and teratogenic effects at doses not significantly higher than those used in humans.[1] While several large-scale human observational studies and registries have not found a definitive association between mebendazole use during pregnancy and an increased risk of major birth defects or miscarriage, its use is generally advised against, especially during the first trimester, unless the potential benefit to the mother is judged to outweigh the potential risk to the fetus.[1]
• Lactation: It is unknown whether mebendazole or its metabolites are excreted in human breast milk. Due to the lack of data, caution should be exercised when administering the drug to a nursing mother.[28]
• Pediatrics: The safety and efficacy of mebendazole have not been established in children younger than one year of age. The specific risk of convulsions in this age group makes its use in infants particularly concerning.[22]

Section 6: Contraindications, Warnings, and Drug Interactions

While mebendazole is a widely used and generally safe medication, there are specific circumstances where its use is contraindicated, along with important warnings and clinically significant drug interactions that healthcare professionals must consider to ensure patient safety.

6.1 Contraindications

The sole absolute contraindication for mebendazole is a history of known hypersensitivity (allergy) to mebendazole or any of the excipients present in the pharmaceutical formulation.[22]

6.2 Warnings and Precautions

Several important warnings and precautions are associated with the use of mebendazole:

• Concomitant Use with Metronidazole: This is the most critical warning associated with mebendazole. Co-administration with the antibiotic metronidazole should be avoided due to postmarketing reports of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).[1] SJS and TEN are rare but severe and potentially fatal hypersensitivity reactions affecting the skin and mucous membranes. The mechanism appears to be a unique, synergistic toxicity rather than a simple pharmacokinetic interaction, possibly involving an immune-mediated pathway triggered by the combination of the two drugs. This specific and idiosyncratic interaction underscores the need for heightened pharmacovigilance and strict avoidance of this drug pairing.
• Risk of Convulsions in Infants: As previously noted, convulsions have been reported in infants under the age of one year during post-marketing surveillance.[22] Although a causal link has not been definitively established, the lack of extensive safety data in this age group warrants extreme caution. Mebendazole should only be used in children aged 1-2 years if the potential benefit justifies the potential risk.[45]
• Hematologic Effects with High-Dose Therapy: Patients receiving mebendazole at doses higher than those recommended for standard intestinal worm infections or for prolonged durations must be monitored for hematologic toxicity. Regular blood count monitoring is essential to detect the potential onset of neutropenia or agranulocytosis.[22]
• Hepatic Impairment: Mebendazole is extensively metabolized by the liver. In patients with pre-existing liver disease or impaired biliary function, drug clearance may be reduced, leading to higher systemic plasma concentrations and an increased risk of toxicity. The drug should be used with caution in this population.[11]

6.3 Clinically Significant Drug Interactions

Mebendazole is subject to several clinically significant drug-drug interactions, primarily related to its metabolism via the cytochrome P450 enzyme system. These are summarized in Table 3.

Table 3: Clinically Significant Drug Interactions with Mebendazole

Interacting Drug	Mechanism	Clinical Effect	Management Recommendation
Metronidazole	Pharmacodynamic Synergism (Mechanism not fully elucidated)	Increased risk of severe skin reactions: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).	Avoid concomitant use. 1
Cimetidine	Inhibition of Hepatic Metabolism (CYP450 enzymes)	Increases plasma concentrations of mebendazole, potentially increasing the risk of systemic toxicity.	Use with caution; monitor for adverse effects, especially with high-dose therapy. 8
Phenytoin, Carbamazepine	Induction of Hepatic Metabolism (CYP450 enzymes)	Decreases plasma concentrations of mebendazole, which may reduce its efficacy for systemic infections (e.g., hydatid disease) or in oncology.	Monitor for lack of efficacy. Dose adjustments may be necessary for systemic indications. 8
Deferiprone	Pharmacodynamic Synergism	Potential for additive risk of neutropenia or agranulocytosis.	Avoid concomitant use. If unavoidable, monitor absolute neutrophil count frequently. 8

Section 7: Comparative Efficacy Analysis: Mebendazole versus Albendazole

Mebendazole and albendazole are the two primary benzimidazole anthelmintics used globally for the treatment of soil-transmitted helminth (STH) infections. While they share a similar mechanism of action and are often used interchangeably, head-to-head clinical trials have revealed crucial differences in their efficacy spectra. These differences have significant implications for both individual patient treatment and large-scale public health deworming strategies.

7.1 Head-to-Head Efficacy

A key randomized controlled trial directly compared the efficacy of single-dose and triple-dose regimens of both mebendazole (500 mg) and albendazole (400 mg) against the major STHs.[47] The findings, summarized in Table 4, highlight a clear pattern of differential activity.

• Hookworm (Ancylostoma duodenale, Necator americanus): Albendazole is demonstrably superior to mebendazole for the treatment of hookworm infections. A single dose of albendazole achieved a cure rate of 69%, which was significantly higher than the 29% cure rate for single-dose mebendazole. Remarkably, a single dose of albendazole was even more effective than a triple-dose regimen of mebendazole, which only cured 54% of infections.[47]
• Whipworm (Trichuris trichiura): Mebendazole shows a modest efficacy advantage over albendazole for whipworm. The highest cure rate observed in the trial was 71%, achieved with a triple dose of mebendazole. In contrast, a triple dose of albendazole cured 56% of infections. However, the overall efficacy of both drugs against T. trichiura is considered suboptimal, with even the best regimen failing to cure a substantial portion of infected individuals.[47]
• Roundworm (Ascaris lumbricoides): Both mebendazole and albendazole are highly effective against roundworm. Single-dose regimens of either drug achieved excellent cure rates, typically exceeding 90%.[47]
• Tapeworm (Taenia spp.): For tapeworm infections, multi-day dosing is critical. Triple-dose regimens of either drug were highly effective, curing all observed infections. In contrast, single doses of either drug were only about 50% effective.[47]

Table 4: Comparative Efficacy of Mebendazole vs. Albendazole for Major Soil-Transmitted Helminths

Parasite	Treatment Regimen	Mebendazole Cure Rate (95% CI)	Albendazole Cure Rate (95% CI)
Hookworm	Single Dose	29% (20–45%)	69% (55–81%)
Hookworm	Triple Dose	54% (46–71%)	92% (81–98%)
Whipworm	Single Dose	40%	34%
Whipworm	Triple Dose	71% (57–82%)	56%
Roundworm	Single Dose	>90%	>90%

Data adapted from [47]

7.2 Dosing Regimens and Clinical Implications

The comparative data strongly support the use of multi-day (triple-dose) regimens over the widely used single-dose approach to achieve high cure rates for both hookworm and whipworm infections.[47] The choice between a convenient single 500 mg dose and a more effective 3-day course of 100 mg twice daily represents a classic clinical trade-off between maximizing patient adherence and achieving the highest possible parasitological cure rate.

7.3 Strategic Use in Public Health

The nuanced differences in efficacy between mebendazole and albendazole are magnified at the population level and have profound implications for public health policy. The choice of drug for mass drug administration (MDA) programs should not be arbitrary but must be guided by local epidemiological data. Using an anthelmintic that is suboptimal for the predominant local parasite can lead to widespread treatment failure and the persistence of infection despite significant investment in deworming campaigns.

For example, exclusively using mebendazole in a region where hookworm is the primary endemic STH could result in a cure rate as low as 29% with a single-dose regimen, whereas using albendazole could achieve a 69% cure rate.[47] Scaled across a population of millions, this difference represents a massive disparity in public health impact. Therefore, an evidence-based approach is imperative:

• In regions where hookworm is the predominant infection, albendazole is the clear drug of choice.[47]
• In areas with a high prevalence of whipworm, mebendazole may be preferred, ideally as a multi-dose regimen.[47]
• In co-endemic areas where all STHs are common, public health programs should consider strategies such as alternating between albendazole and mebendazole in successive MDA rounds to ensure broad coverage against all relevant parasites.[47]

Section 8: Investigational Applications in Oncology

In recent years, mebendazole has emerged as one of the most promising candidates for drug repurposing in oncology. A substantial body of preclinical evidence, coupled with early-phase clinical trials, suggests that this well-established anthelmintic possesses potent and multi-faceted anti-cancer properties.

8.1 Rationale for Repurposing

Mebendazole embodies many of the ideal characteristics for a repurposed drug, making it an attractive and low-risk candidate for investigation in cancer therapy [13]:

• Extensive Safety Data: Having been in human use for over five decades, its safety and toxicity profile at standard doses is well-understood.
• Favorable Pharmacokinetics: It is orally bioavailable and, crucially, possesses the ability to cross the blood-brain barrier, making it a candidate for treating brain malignancies.
• Low Cost and Accessibility: As a widely available generic medication, it represents an affordable therapeutic option.
• Ease of Administration: Its formulation as an oral tablet simplifies dosing and improves patient convenience.

8.2 Preclinical Evidence and Anti-Cancer Mechanisms

Mebendazole has demonstrated significant anti-tumor activity in a wide array of preclinical models, including both in vitro cancer cell lines and in vivo animal xenograft models. Its efficacy has been shown against numerous cancer types, such as glioblastoma, medulloblastoma, colorectal cancer, breast cancer, lung cancer, pancreatic cancer, and adrenocortical carcinoma.[4]

Its anti-cancer effects are not mediated by a single mechanism but by a multi-pronged attack on several key pathways essential for tumor growth, survival, and metastasis [13]:

• Tubulin Polymerization Inhibition: As its primary mechanism, mebendazole disrupts microtubule formation, leading to mitotic arrest and the induction of apoptosis in rapidly dividing cancer cells.[17]
• Anti-Angiogenesis: It inhibits the formation of new blood vessels (angiogenesis), which are critical for supplying tumors with oxygen and nutrients. This effect is mediated, in part, through the inhibition of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) signaling.[4]
• Inhibition of Pro-Survival Pathways: Mebendazole has been shown to interfere with critical cancer cell survival pathways, including the inactivation of the anti-apoptotic protein Bcl-2.[1]
• Inhibition of the Hypoxia Response: Recent research has uncovered a novel and highly significant mechanism: mebendazole disrupts the transcriptional activity of Hypoxia-Inducible Factors 1 and 2 (HIF-1α and HIF-2α).[49] The HIF pathway is the master regulator of the cellular response to low-oxygen (hypoxic) conditions, which are characteristic of the solid tumor microenvironment. Hypoxia is a major driver of therapeutic resistance. By inhibiting HIFs, mebendazole may disable a primary survival mechanism of cancer cells, potentially re-sensitizing hypoxic and resistant tumors to conventional chemotherapy and radiation. This positions mebendazole not just as a cytotoxic agent but as a potential "resistance breaker."
• Synergy with Conventional Therapies: Preclinical studies have consistently shown that mebendazole can act synergistically with ionizing radiation and various chemotherapeutic agents. It has also been reported to stimulate an anti-tumoral immune response.[13]

8.3 Clinical Trial Evidence

The promising preclinical data has led to the initiation of several clinical trials investigating mebendazole in cancer patients. The most mature data comes from a Phase 1 study in patients with brain tumors.

Table 5: Summary of Key Clinical Trials of Mebendazole in Oncology

Trial ID	Cancer Type	Phase	Regimen	Key Findings (Safety & Efficacy)
NCT01729260	Newly Diagnosed High-Grade Glioma (Adult)	Phase 1	Mebendazole (up to 200 mg/kg/day) + standard temozolomide.	Safety: Regimen was safe and well-tolerated long-term. Dose-limiting toxicity was reversible Grade 3 elevation of liver enzymes (ALT/AST). Efficacy: Median overall survival was 21 months. Median PFS was 13.1 months for patients on drug >1 month vs. 9.2 months for <1 month. Results are encouraging but not definitive. 26
NCI-2017-00550	Recurrent/Refractory Pediatric Brain Tumors	Phase 1	Mebendazole monotherapy dose escalation.	To determine the maximum tolerated dose (MTD) and safety profile in pediatric patients. 43
NCT03925662	Colon Cancer	Phase 1/2	Mebendazole in combination with other therapies.	Trial is underway to evaluate safety and efficacy. 26

In addition to formal trials, there are case reports of long-term disease control in patients with advanced adrenocortical carcinoma treated with mebendazole.[42] Some observational data also suggests that adding mebendazole to standard chemotherapy may slow disease progression in patients with metastatic colorectal cancer.[52]

8.4 Future Directions in Cancer Therapy

The existing body of evidence strongly supports the continued investigation of mebendazole as a repurposed anti-cancer agent. Its ability to cross the blood-brain barrier makes it a particularly compelling candidate for both adult and pediatric brain cancers.[25] Its novel mechanism of HIF inhibition warrants further exploration as a strategy to overcome therapeutic resistance in a wide range of solid tumors.[49] Larger, randomized Phase 2 and Phase 3 clinical trials are now necessary to definitively establish its efficacy, determine optimal dosing and scheduling, and identify its precise role within the broader landscape of cancer therapy, whether as a monotherapy or in combination with existing treatments.

Section 9: Regulatory and Manufacturing Landscape

Mebendazole's journey from its development in the 1970s to its current global status reveals a bifurcated existence. It is simultaneously a low-cost, widely accessible staple of global public health and a niche, commercially fragile prescription product in some high-income countries. This unique regulatory and commercial history has significant implications for its future development, particularly for its potential repurposing in oncology.

9.1 Regulatory History and Status

Mebendazole was developed by Janssen Pharmaceutica in Belgium and first introduced for human use in 1971.[1] Its 100 mg chewable tablet formulation, under the brand name Vermox™, received its initial U.S. FDA approval in 1974 (NDA 017841).[24]

In a notable turn, marketing of the original Vermox™ was discontinued in the United States in 2006 for commercial reasons, not due to any safety or efficacy concerns.[24] The drug was later reintroduced to the U.S. market through new regulatory approvals, including Emverm™ (100 mg chewable tablet, approved in 2016) and a new formulation of Vermox™ Chewable (500 mg tablet, approved in 2016) under the 505(b)(2) pathway.[24] The 500 mg chewable tablet was also granted Orphan Drug Designation by the FDA for the treatment of soil-transmitted helminths.[24]

9.2 Global Availability and Prescription Status

Mebendazole's status as a globally important medicine is solidified by its inclusion on the World Health Organization's List of Essential Medicines.[1] This status reflects its critical role in public health, particularly in low- and middle-income countries. Johnson & Johnson, the original developer, maintains a large-scale donation program, providing hundreds of millions of doses of 500 mg mebendazole tablets annually for mass deworming campaigns in endemic regions.[24]

The prescription status of mebendazole varies significantly around the world, reflecting different regulatory philosophies and public health needs:

• United States: It is available strictly as a prescription-only (Rx-only) medication.[1] Interestingly, despite its FDA approval, the 500 mg chewable Vermox™ tablet is not planned for commercial sale in the U.S. and is intended primarily for the international donation program.[24]
• United Kingdom: Mebendazole has a mixed status. It can be purchased over-the-counter from a pharmacy (as a 'P' medicine) for adults and children over two years of age. However, a prescription (POM) is required for its use in younger children (aged 6 months to 2 years).[1]
• European Union: The status varies by member state. It is approved for use in most EU countries.[45] In some, like Ireland, it is available for purchase from a pharmacy following a consultation, while in others, such as Germany, a physician's prescription is generally required.[55]
• Low- and Middle-Income Countries: In many tropical and subtropical countries where helminth infections are endemic, mebendazole is widely available over-the-counter at low cost.[26]

This regulatory landscape highlights a significant disconnect. The drug's primary volume and public health impact are concentrated in developing nations, where it is an accessible commodity. In contrast, its presence in high-income markets like the U.S. is more tenuous and commercially driven. This lack of a strong commercial driver in major Western markets could pose a challenge to securing the substantial investment required for large-scale Phase 3 oncology trials, potentially leaving its development in this area reliant on academic and government-funded research.

9.3 Chemical Synthesis Overview

Mebendazole is a synthetic compound produced through multi-step organic synthesis.[57] As a benzimidazole derivative, its synthesis involves the construction of the core heterocyclic ring system. A common industrial pathway utilizes 3,4-diaminobenzophenone as a key chemical intermediate.[11]

One described synthetic route begins with starting materials such as o-dichlorobenzene and benzoyl chloride. These undergo reactions of condensation and ammoniation to build the necessary precursors.[57] The final and characteristic step is a cyclization reaction. The 3,4-diaminobenzophenone intermediate is reacted with a reagent that provides the carbamate side chain, such as methyl cyanocarbamate or N-methoxycarbonyl-S-methylthiourea. This reaction closes the imidazole ring, forming the final mebendazole structure.[11] The synthesis and purification of key intermediates, such as o-chloraniline, are also critical steps in the overall manufacturing process.[58]

Works cited

1. Mebendazole - Wikipedia, accessed August 26, 2025, https://en.wikipedia.org/wiki/Mebendazole
2. Mebendazole | C16H13N3O3 | CID 4030 - PubChem, accessed August 26, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Mebendazole
3. Mebendazole | CAS 31431-39-7 | SCBT - Santa Cruz Biotechnology, accessed August 26, 2025, https://www.scbt.com/p/mebendazole-31431-39-7
4. Mebendazole (NSC 184849, R 17635, CAS Number: 31431-39-7) | Cayman Chemical, accessed August 26, 2025, https://www.caymanchem.com/product/18872/mebendazole
5. MEBENDAZOLE - CAMEO Chemicals - NOAA, accessed August 26, 2025, https://cameochemicals.noaa.gov/chemical/20586
6. www.nhs.uk, accessed August 26, 2025, https://www.nhs.uk/medicines/mebendazole/#:~:text=Mebendazole%20Brand%20names%3A%20Ovex%2C%20Vermox
7. Mebendazole: a medicine to treat worms - NHS, accessed August 26, 2025, https://www.nhs.uk/medicines/mebendazole/
8. Emverm, Vermox (mebendazole) dosing, indications, interactions, adverse effects, and more, accessed August 26, 2025, https://reference.medscape.com/drug/emverm-vermox-mebendazole-342658
9. Mebendazole | Drug Lookup | Pediatric Care Online | American ..., accessed August 26, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5318/Mebendazole
10. Mebendazole 31431-39-7 | Tokyo Chemical Industry Co., Ltd.(APAC), accessed August 26, 2025, https://www.tcichemicals.com/OP/en/p/M2273
11. Mebendazole | 31431-39-7 - ChemicalBook, accessed August 26, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8700094.htm
12. Physical parameters for mebendazole and dicarboxylic acids - ResearchGate, accessed August 26, 2025, https://www.researchgate.net/figure/Physical-parameters-for-mebendazole-and-dicarboxylic-acids_tbl1_272266438
13. Mebendazole: pharmacokinetics, applications and side effects - ChemicalBook, accessed August 26, 2025, https://www.chemicalbook.com/article/mebendazole-pharmacokinetics-applications-and-side-effects.htm
14. VERMOX® - Medsafe, accessed August 26, 2025, https://www.medsafe.govt.nz/profs/datasheet/v/Vermoxtabsusp.pdf
15. What is the mechanism of Mebendazole? - Patsnap Synapse, accessed August 26, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-mebendazole
16. Mebendazole - PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/484964/
17. Mebendazole as a Candidate for Drug Repurposing in Oncology: An ..., accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/
18. Chemical structure of mebendazole. | Download Scientific Diagram - ResearchGate, accessed August 26, 2025, https://www.researchgate.net/figure/Chemical-structure-of-mebendazole_fig1_287446431
19. Antihelmintic Drugs: A Comprehensive Review of Methods of Synthesis and Mechanism, accessed August 26, 2025, https://www.jneonatalsurg.com/index.php/jns/article/view/4106
20. Mebendazole: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/drugs/DB00643
21. How Safe is Mebendazole? A Close Look at the John Hopkins Study | Integrative Holistic Cancer Therapy, Houston, Texas - Omega Precision Oncology, accessed August 26, 2025, https://i2b.us/how-safe-is-mebendazole-a-close-look-at-the-john-hopkins-study/
22. Mebendazole - StatPearls - NCBI Bookshelf, accessed August 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557705/
23. Mebendazole: Package Insert / Prescribing Information - Drugs.com, accessed August 26, 2025, https://www.drugs.com/pro/mebendazole.html
24. 208398Orig1s000 - accessdata.fda.gov, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208398Orig1s000CrossR.pdf
25. Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers - MDPI, accessed August 26, 2025, https://www.mdpi.com/1422-0067/24/2/1334
26. Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7817892/
27. Mebendazole: MedlinePlus Drug Information, accessed August 26, 2025, https://medlineplus.gov/druginfo/meds/a682315.html
28. MEBENDAZOLE oral - MSF Medical Guidelines, accessed August 26, 2025, https://medicalguidelines.msf.org/en/viewport/EssDr/english/mebendazole-oral-16684091.html
29. Emverm (mebendazole) FDA Approval History - Drugs.com, accessed August 26, 2025, https://www.drugs.com/history/emverm.html
30. Mebendazole Monograph for Professionals - Drugs.com, accessed August 26, 2025, https://www.drugs.com/monograph/mebendazole.html
31. Therapeutic uses of Mebendazole 500mg and Mebendazole 100mg | Vinmec, accessed August 26, 2025, https://www.vinmec.com/eng/blog/uses-of-mebendazole-500mg-and-mebendazole-100mg-en
32. How and when to take mebendazole - NHS, accessed August 26, 2025, https://www.nhs.uk/medicines/mebendazole/how-and-when-to-take-mebendazole/
33. Mebendazole Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 26, 2025, https://www.drugs.com/dosage/mebendazole.html
34. U.S. FDA Approves Vermox™ Chewable (Mebendazole) For Treatment of Children and Adults With Roundworm and Whipworm Infections, accessed August 26, 2025, https://www.jnj.com/media-center/press-releases/us-fda-approves-vermoxtm-chewable-mebendazole-for-treatment-of-children-and-adults-with-roundworm-and-whipworm-infections
35. About mebendazole - NHS, accessed August 26, 2025, https://www.nhs.uk/medicines/mebendazole/about-mebendazole/
36. Mebendazole for worm infections - Medicines For Children, accessed August 26, 2025, https://www.medicinesforchildren.org.uk/medicines/mebendazole-for-worm-infections/
37. Who can and cannot take mebendazole - NHS, accessed August 26, 2025, https://www.nhs.uk/medicines/mebendazole/who-can-and-cannot-take-mebendazole/
38. Mebendazole (oral route) - Side effects & dosage - Mayo Clinic, accessed August 26, 2025, https://www.mayoclinic.org/drugs-supplements/mebendazole-oral-route/description/drg-20064631
39. Mebendazole Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 26, 2025, https://www.drugs.com/sfx/mebendazole-side-effects.html
40. Side effects of mebendazole - NHS, accessed August 26, 2025, https://www.nhs.uk/medicines/mebendazole/side-effects-of-mebendazole/
41. This label may not be the latest approved by FDA. For current ..., accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208398s001lbl.pdf
42. Mebendazole and temozolomide in patients with newly diagnosed ..., accessed August 26, 2025, https://academic.oup.com/noa/article/3/1/vdaa154/5979487
43. Mebendazole in Treating Patients with Recurrent, Refractory, or Progressive Pediatric Brain Tumors - NCI, accessed August 26, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2017-00550
44. Taking mebendazole with other medicines and herbal supplements - NHS, accessed August 26, 2025, https://www.nhs.uk/medicines/mebendazole/taking-mebendazole-with-other-medicines-and-herbal-supplements/
45. Art. 45 AR - CMDh_021_2009_Rev04_2014 04 - tracked, accessed August 26, 2025, https://sukl.gov.cz/wp-content/uploads/2025/02/Mebendazolum-PAR-45.pdf
46. Mebendazole Interactions Checker - Drugs.com, accessed August 26, 2025, https://www.drugs.com/drug-interactions/mebendazole.html
47. Efficacy of Single-Dose and Triple-Dose Albendazole and ..., accessed August 26, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0025003
48. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model | Oncotarget, accessed August 26, 2025, https://www.oncotarget.com/article/11851/text/
49. Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors 1 and 2 in Breast Cancer Cells - Johns Hopkins University, accessed August 26, 2025, https://pure.johnshopkins.edu/en/publications/mebendazole-treatment-disrupts-the-transcriptional-activity-of-hy
50. How Mebendazole Could Revolutionize Non-Traditional Cancer Care| Expert Insights on Integrative Medicine, accessed August 26, 2025, https://www.417integrativemedicine.com/articles/how-mebendazole-could-revolutionize-non-traditional-cancer-care
51. Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide, accessed August 26, 2025, https://clinicaltrials.gov/study/NCT01729260
52. Mebendazole or Fenbendazole - CancerChoices, accessed August 26, 2025, https://cancerchoices.org/therapy/mebendazole-or-fenbendazole/
53. Vermox (mebendazole): Uses, Side Effects, Dosage & More - GoodRx, accessed August 26, 2025, https://www.goodrx.com/vermox/what-is
54. 208398Orig1s000 - accessdata.fda.gov, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208398Orig1s000OtherR.pdf
55. Vermox 100mg Mebendazole 6 Tablets - Meaghers Pharmacy, accessed August 26, 2025, https://www.meagherspharmacy.ie/products/vermox-100mg-mebendazole-tablets-6s
56. Pharmacies & medicine in Germany - IamExpat.de, accessed August 26, 2025, https://www.iamexpat.de/expat-info/german-healthcare-system/pharmacies-medicine-germany
57. Mebendazole synthesis - chemicalbook, accessed August 26, 2025, https://www.chemicalbook.com/synthesis/mebendazole.htm
58. CN105968017A - Mebendazole drug intermediate o-chloroaniline synthesis method - Google Patents, accessed August 26, 2025, https://patents.google.com/patent/CN105968017A/en